Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05844293 · ClinicalTrials.gov registry record · Phase 1
Single Ascending Dose of FXI-GalNAc-siRNA in Healthy Subjects
A Phase 1 study of FXI, sponsored by Sirnaomics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
- 2
- Study locations
NCT05844293: Recruiting Phase 1 study of FXI, sponsored by Sirnaomics.
NCT05844293 is a Phase 1 study of FXI that is actively recruiting participants, run by Sirnaomics. The registered enrollment target is 40 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (33% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05844293, a Phase 1 study of FXI, is actively recruiting participants, sponsored by Sirnaomics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to evaluate safety, tolerability, PK, and PD of SAD of FXI-GalNAc-siRNA administered SC to healthy subjects.
Primary Outcome
Individual plasma concentration data of FXI-GalNAc-siRNA will be used to determine Maximum peak concentration.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG FXI-GalNAc-siRNA
Study Locations (2)
Missouri
- BioPharma - Creve Coeur
Ontario
- BioPharma - Toronto
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2023-05-16 |
| Est. Completion | 2024-06 |
| Phase | Phase 1 |
What NCT05844293 shows while recruiting
NCT05844293 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (33% lower).
The record links to 1 condition, with FXI appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05844293 reports a single indexed study location in Missouri, Ontario.
Frequently Asked Questions
What is clinical trial NCT05844293 about?
NCT05844293 is a clinical study titled "Single Ascending Dose of FXI-GalNAc-siRNA in Healthy Subjects". The purpose of this study is to evaluate safety, tolerability, PK, and PD of SAD of FXI-GalNAc-siRNA administered SC to healthy subjects.
What is the current status of trial NCT05844293?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2023-05-16. Estimated completion is 2024-06.
What conditions does trial NCT05844293 study?
This clinical trial studies the following conditions: FXI.
What interventions are being tested in trial NCT05844293?
The interventions under investigation include: Placebo (OTHER), FXI-GalNAc-siRNA (DRUG).
Who is sponsoring clinical trial NCT05844293?
This trial is sponsored by Sirnaomics, which has 11 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05844293 being conducted?
This trial has 2 study locations across Missouri, Ontario. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05844293's enrollment target sits among peer trials
40 1130th of 2000 higher than 810 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01306019 · 40 participants · Phase 1
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
- NCT01608152 · 40 participants
Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors
- NCT01668082 · 40 participants · NA
An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection
- NCT02015013 · 40 participants · Phase 2
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI